Lannett Sees Boost From Adderall Shortages And Pricing Reprieve
Firm Also Makes ANDA Deals And Gets FDA Nod For Seymour Plant
In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.
You may also be interested in...
Teva, one of the largest manufacturers and suppliers of branded and generic Adderall, the renowned treatment for ADHD and narcolepsy, has responded to claims.
Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.
Lannett continued to talk up its prospects of launching numerous low-competition, high-value products in the coming years – as it disclosed another sizeable loss for its 2022/23 financial year.